Cytochrome P450 2C9 Inducers

Cytochrome P450 2C19 Inducers

Cytochrome P450 2C8 Inhibitors

Organic Anion Transporting Polypeptide 1B1 Inhibitors

Organic Anion Transporting Polypeptide 1B3 Inhibitors

Cytochrome P450 3A Inhibitors

Cytomegalovirus DNA Terminase Complex Inhibitor

DNA Terminase Complex Inhibitors

<section class="Section" data-sectioncode="34089-3"><a name="S11"></a><a name="section-10"></a><h1>11 DESCRIPTION</h1>PREVYMIS contains letermovir, an inhibitor of the CMV DNA terminase complex, and is administered orally or by intravenous infusion.PREVYMIS is available as 240 mg and 480 mg tablets. PREVYMIS tablets contain either 240 mg or 480 mg of letermovir and the following inactive ingredients: colloidal silicon dioxide, croscarmellose sodium, magnesium stearate, microcrystalline cellulose, povidone 25, and film-coated with a coating material containing the following inactive ingredients: hypromellose 2910, iron oxide red (only for 480 mg tablets), iron oxide yellow, lactose monohydrate, titanium dioxide, and triacetin. Carnauba wax is added as a polishing agent.PREVYMIS is also available as 240 mg and 480 mg injection for intravenous infusion. PREVYMIS injection is a clear, preservative-free sterile solution and may contain a few small translucent or white particles in single-dose vials of either 240 mg or 480 mg per vial. Each 1 mL of solution contains 20 mg letermovir, hydroxypropyl betadex (150 mg), sodium chloride (3.1 mg), sodium hydroxide (1.2 mg), and Water for Injection, USP. The amount of sodium hydroxide may be adjusted to achieve a pH of approximately 7.5.Letermovir has a molecular formula of C29H28F4N4O4 and a molecular weight of 572.55. The chemical name for letermovir is (4S)-2-{8-Fluoro-2-[4-(3- methoxyphenyl)piperazin-1-yl]-3-[2-methoxy-5- (trifluoromethyl)phenyl]-3,4-dihydroquinazolin-4-yl}acetic acid. Letermovir is very slightly soluble in water.The chemical structure of letermovir is:<img alt="Chemical Structure" src="prevymis-01.jpg"/></section>

PREVYMIS

letermovir

12 ML letermovir 20 MG/ML Injection

Prevymis

12 ML letermovir 20 MG/ML Injection [Prevymis]

24 ML letermovir 20 MG/ML Injection

24 ML letermovir 20 MG/ML Injection [Prevymis]

letermovir 240 MG Oral Tablet

letermovir 240 MG Oral Tablet [Prevymis]

letermovir 480 MG Oral Tablet

letermovir 480 MG Oral Tablet [Prevymis]

Psoriasis (PsO)

Psoriatic Arthritis (PsA)

Ankylosing Spondylitis (AS)

Nonradiographic Axial Spondyloarthritis

Taltz

Juvenile Idiopathic Arthritis

Hidradenitis Suppurativa (HS)

Cosentyx

Siliq

Tremfya

Crohn's Disease (CD)

Ulcerative Colitis (UC)

Stelara

Skyrizi

Ilumya

Migraine

Cluster Headache

Migraine Prevention

Emgality

Qulipta

Acute Migraine

Ubrelvy

Nurtec ODT

Vyepti

Aimovig

Ajovy

Breast Cancer: HR+ (HER2-)

Verzenio

Ibrance

Kisqali

Atopic Dermatitis (Eczema)

Cibinqo

Eucrisa

Asthma (injectable)

Asthma OCS Dependent

Nasal Polyposis

Eosinophilic Esophagitis (EoE)

Prurigo Nodularis

Dupixent

Opzelura

Adbry

NSCLC ALK+ OR ROS1+ Disease

Lorbrena

Alecensa

Alunbrig

NSCLC cMET Mutation

Xalkori

Rheumatoid Arthritis (RA)

Xeljanz

Uveitis

Graft Versus Host Disease (GVHD)

Orencia

COVID-19 Treatment

Alopecia Areata

Olumiant

Multiple Sclerosis (MS)

Secondary Progressive Multiple Sclerosis

Zeposia

Rinvoq

Entyvio

Report Adverse Event 

Prescribing Information

Medication Guide 

Pharmacy List 

Prior Authorization Checklist 

Coverage Authorization Request 

Appeals Checklist 

Coverage Authorization Appeals 

Merck Access Program Enrollment Form

Merck Access Program Enrollment Form - Online

Enroll in Patient Savings Program 

Other HCP Resources 

Patient Brochure

Side Effects 

Instructions For Use: CMV

Submit MSL Request 

Other HCP Resources: Access Forms